Pancreatic cancer is a highly malignant disease that is associated with poor prognosis. One hallmark of pancreatic cancer is excessive desmoplasia, characterized by fibrous or connective tissue growth and altered tumor stroma. Pancreatic stellate cells (PSCs) comprise a mesenchymal cell type that contributes to pancreas fibrosis and cancer progression. PSME3 is a regulatory subunit of the proteasome that is expressed in various cancers such as breast, ovarian, and pancreatic. Notably, PSME3 modulates lactate secretion in pancreatic cancer, suggesting a potential function in regulating pancreas fibrosis. However, the role of PSME3 in pancreatic cancer cell (PCC)-PSC interactions remains unclear. The current study, for the first time, explored the mechanism involved in PSME3-mediated PCC-PSC interactions. IHC showed that PSME3 is highly expressed in PCCs, and this was found to correlate with tumor differentiation. RNA interference (RNAi) indicated that PSME3 is involved in PCC apoptosis. PCR array and cell co-culture experiments suggested that conditioned culture medium (CM) from PSME3-knockdown PCCs could suppress PSC proliferation by down-regulating TGFB1 secretion. Transcription factor (TF) activation assays showed that PSME3 regulates TGFB1 production by inhibiting activation protein-1 (AP-1). Together, these data demonstrate that PSME3 interacts with AP-1 to regulate TGFB1 secretion in PCCs and promote PSC proliferation. Our results indicate a novel PSME3-regulated association between PSCs and PCCs and provide a promising therapeutic strategy for this malignancy.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6548159 | PMC |
http://dx.doi.org/10.7150/jca.30235 | DOI Listing |
Curr Oncol Rep
January 2025
Lombardi Comprehensive Cancer Center, Georgetown University, 3800 Reservoir Road NW, Washington, DC, 20007, USA.
Purpose Of Review: Neuregulin 1 (NRG1) fusions are rare but actionable oncogenic drivers that occur in a variety of tumor types, including non-small cell lung cancer (NSCLC). These fusions lead to pathophysiologic activation of HER signaling pathways, promoting tumor growth, invasion, and metastasis. Current evidence suggests that NRG1 fusion-positive NSCLC does not respond well to conventional treatments such as immunotherapy and chemotherapy.
View Article and Find Full Text PDFMol Biol Rep
January 2025
School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab, 144411, India.
Pancreatic cancer remains as global health challenge, ranking as the seventh leading cause of cancer-related deaths worldwide with high mortality rates and a low five-year survival rate. Despite advancements in conventional therapies, including surgery, chemotherapy, and radiation, the overall survival rates for pancreatic cancer patients have shown minimal improvement. Consequently, there is an urgent need for alternative therapeutic strategies.
View Article and Find Full Text PDFAnn Surg Oncol
January 2025
Department of Surgery, Weill Cornell Medicine, New York, NY, USA.
Background: Guidelines for some pancreatic neuroendocrine tumors (NETs) have shifted towards active surveillance given the indolent nature of this malignancy. We sought to assess the safety of delayed surgery on colorectal NETs as a surrogate for surveillance.
Methods: Resected, stage I, well-differentiated colorectal primary NETs included in the Surveillance, Epidemiology, and End Results Program from 2010 to 2020 were included.
J Gastroenterol
January 2025
Division of Surgical Oncology, Department of Surgery, University of Alabama at Birmingham (UAB), Birmingham, Alabama, 35294, USA.
Background: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease with a high mortality rate and exhibits a limited response to apoptosis-dependent chemotherapeutic drugs (e.g., gemcitabine, Gem).
View Article and Find Full Text PDFEndocr Relat Cancer
January 2025
T Vandamme, NETwerk and department of Digestive Oncology, University Hospital Antwerp, Edegem, Belgium.
Gastroenteropancreatic neuroendocrine neoplasms(GEP NEN) exhibit substantial biological heterogeneity, impacting clinical management and outcomes. In 2019, the WHO introduced the neuroendocrine tumour(NET) grade 3 (G3) subgroup, characterized by Ki-67>20% and a well-differentiated morphology and poorly differentiated neuroendocrine carcinomas(NEC) (Ki-67>20%). Since this update, questions about the prognostic implications and best treatment strategies for NET G3 and NEC remain.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!